Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Deutsche Biotech Innovativ AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.00 |
52 Week High | €18.00 |
52 Week Low | €3.00 |
Beta | 0.23 |
1 Month Change | -28.91% |
3 Month Change | -80.00% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -53.85% |
Recent News & Updates
Recent updates
Shareholder Returns
DBI | DE Biotechs | DE Market | |
---|---|---|---|
7D | -21.1% | -1.6% | -0.9% |
1Y | n/a | -26.8% | 4.5% |
Return vs Industry: Insufficient data to determine how DBI performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how DBI performed against the German Market.
Price Volatility
DBI volatility | |
---|---|
DBI Average Weekly Movement | 22.6% |
Biotechs Industry Average Movement | 5.2% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.7% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: DBI's share price has been volatile over the past 3 months.
Volatility Over Time: DBI's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | n/a | Bernd Wegener | www.dbi-ag.de |
Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy that has completed the Phase I/II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, neurodermatitis, pharyngitis, and Alzheimer's diseases.
Deutsche Biotech Innovativ AG Fundamentals Summary
DBI fundamental statistics | |
---|---|
Market cap | €2.84m |
Earnings (TTM) | -€236.44k |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-12.0x
P/E RatioIs DBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DBI income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €236.44k |
Earnings | -€236.44k |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.25 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did DBI perform over the long term?
See historical performance and comparison